Streetbeat News

Price Targets

PODD

Morgan Stanley analyst Patrick Wood has maintained an Equal-Weight rating on Insulet (NASDAQ:PODD) and lowered the price target from $208 to $185.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:30 pm

DXCM

Morgan Stanley analyst Patrick Wood has maintained an Equal-Weight rating on DexCom (NASDAQ:DXCM) and lowered the price target from $131 to $98.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:28 pm

UPS

Raymond James analyst Patrick Tyler Brown maintains a Strong Buy rating on United Parcel Service (UPS) but lowers the price target from $205 to $200.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:24 pm

SBSW

JP Morgan analyst Dominic O'Kane maintains an Overweight rating on Sibanye Stillwater (NYSE:SBSW) but lowers the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:24 pm

HMY

JP Morgan analyst Luke Nelson has maintained a Neutral rating on Harmony Gold Mining Co (NYSE:HMY) and lowered the price target from $5.4 to $3.8.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:21 pm

TRMB

Piper Sandler analyst Clarke Jeffries has reiterated a Neutral rating on Trimble (NASDAQ:TRMB) and maintained a $51 price target.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:17 pm

DFIN

Needham analyst Kyle Peterson maintains a Buy rating on Donnelley Financial Solns (NYSE:DFIN) and raises the price target from $56 to $65.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:13 pm

ALNY

Raymond James analyst Gary Nachman has initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $208.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:11 pm

NKE

Morgan Stanley analyst Alex Kurtz has reiterated an Overweight rating on Nike (NYSE:NKE) and maintained a price target of $126.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:10 pm

ABBV

Raymond James analyst Gary Nachman has initiated coverage on AbbVie (NYSE:ABBV) with an Outperform rating and a price target of $177.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:08 pm